SCHEMBL21708010

SCHEMBL21708010

CCOC(=O)c1csc(Nc2ccc(C(=O)O)cc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.64
SMN1; SMN2 Q16637 5/20 0.61
RAB9A P51151 2/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 4/20 0.58
MAPK1 P28482 2/20 0.58
HSP90AA1 P07900 1/20 0.58
CA12 O43570 8/20 0.57
CA1 P00915 8/20 0.57
CA2 P00918 8/20 0.57
CA9 Q16790 8/20 0.57
LMNA P02545 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
CRHBP P24387 1/20 0.56
CRHR2 Q13324 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4789312 0.88 SMN1; SMN2 (0.69) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL21708021 0.88 MAPT (0.68) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL21708008 0.87 KDM1A (0.67) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL10464406 0.86 MAPT (0.65) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL5041112 0.86 EGFR (0.73) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL790315 0.85 MAPT (0.64) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL525606 0.85 MAOA (0.64) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL20530863 0.83 SMN1; SMN2 (0.72) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL21708012 0.82 GAA (0.66) GAASMN1; SMN2RAB9ANPC1MAPT
SCHEMBL18002737 0.82 MAPT (0.56) GAASMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A GAA 3974/4885SMN1; SMN2 1685/4885RAB9A 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.